A Phase 3 interventional study of Ixekizumab and Adalimumab in Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis, sponsored by Eli Lilly and Company. Active, not recruiting at 43 sites in 12 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Arthritis, Juvenile with a site in Germany — 14 open to participants now, 17 under way, 11 of them phase 3. Arthritis, Juvenile · Germany.
Among the 53 studies in Arthritis, Juvenile with a site in Germany, this one is the 20th largest by enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2021, is one of 32 in phase 3, reaches primary completion later than 0 of the 16 other live ones, and was the 38th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.
Browse Arthritis, Juvenile studies →14 of the 53 studies in Arthritis, Juvenile with a site in Germany are open now. Recruiting first, the newest first:
Alfasigma S.p.A. · Sites in Germany, Belgium, Czechia and 6 more countries
Ages 8–18
Alfasigma S.p.A. · Sites in Germany, France, United Kingdom
Ages 8–18
Duke University · Sites in Germany, United States, Italy and 1 more country
Ages 2–21
Novartis Pharmaceuticals · Sites in Germany, United States, Canada and 5 more countries
Ages 1+
Bristol-Myers Squibb · Sites in Germany, United States, Brazil and 8 more countries
Ages 5–17
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 5 · Phase 3 33 · Phase 4 1
First in 1991; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 101 is above the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 86 across the 45 interventional studies, 438 across the 8 observational. Of the 34 that completed or were terminated, 22 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 53 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 4 studies filed under Arthritis, Juvenile — fewer than ten, so there is no comparison to draw.
2 of the studies in Arthritis, Juvenile with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07554495Phase 3Alfasigma S.p.A.Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents | 2027-06 |
| NCT07203001Novartis PharmaceuticalsA Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease | 2027-04-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 53 studies in Arthritis, Juvenile with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The reason for this study is to see if the study drug ixekizumab is safe and effective in children with juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) (including juvenile onset ankylosing spondylitis [JoAS]) and juvenile psoriatic arthritis (JPsA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants received subcutaneous (SC) ixekizumab from week 0 to week 16, following dosing regimens based on body weight: * Greater than (\>) 50.0 kg: Starting dose 160 mg at week 0, then 80 mg SC every 4 weeks (Q4W) from week 2 to week 16. * 25.0-50.0 kg: Starting dose 80 mg at week 0, then 40 mg SC Q4W from week 2 to week 16. * 10.0 to less than (\<) 25.0 kg: Starting dose 40 mg at week 0, then 20 mg SC Q4W from week 2 to week 16.
Drug: Ixekizumab
Participants received SC adalimumab from week 0 to week 16, following dosing regimens based on body weight: * Greater than or equal to (≥) 30.0 kg: 40 mg SC every 2 weeks (Q2W). * 10.0 to \<30.0 kg: 20 mg SC Q2W.
Drug: Adalimumab
Administered SC
Also known as: LY2439821
Administered SC
Percentage of Participants Achieving Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 (Ixekizumab - OLT Period)
JIA ACR, is comprised of 6 variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]). A JIA ACR30 response is defined as at least 30% improvement from baseline in at least 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by more than 30%.
Time frame: Week 16
Percentage of Participants Achieving JIA ACR 30 (Adalimumab - OLT Period)
JIA ACR, is comprised of 6 variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]). A JIA ACR30 response is defined as at least 30% improvement from baseline in at least 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by more than 30%.
Time frame: Week 16
Percentage of Participants Achieving JIA ACR 50/70/90/100 (OLT Period)
JIA ACR, is comprised of 6 core set variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]). A JIA ACR 50/70/90 response is defined as a greater than or equal to (≥) 50/70/90/100% improvement from baseline in at least 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by more than 30%.
Time frame: Week 16
Percentage of Participants Achieving JIA ACR 30/50/70/90/100 (OLE Period)
JIA ACR, is comprised of 6 core set variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]). A JIA ACR 30/50/70/90 response is defined as a greater than or equal to (≥) 30/50/70/90/100% improvement from baseline in at least 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by more than 30%.
Time frame: Week 104
Change From Baseline in Psoriasis Area and Severity Index (PASI) for Juvenile Psoriatic Arthritis (JPsA) Participants With at Least 3% Body Surface Area (BSA) at Baseline (OLT Period)
The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling (S), redness (R), and plaque induration/infiltration thickness (T) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Severity is rated for each index (R, S, T) on a 0 to 4 scale (0 for no involvement up to 4 for severe involvement): 0 = none 1. = slight 2. = moderate 3. = severe 4. = very severe The various body regions are weighted to reflect their respective proportion of BSA.
Time frame: Baseline, Week 16
Change From Baseline in Psoriasis Area and Severity Index (PASI) for Juvenile Psoriatic Arthritis (JPsA) Participants With at Least 3% Body Surface Area (BSA) at Baseline (OLE Period)
The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling (S), redness (R), and plaque induration/infiltration thickness (T) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Severity is rated for each index (R, S, T) on a 0 to 4 scale (0 for no involvement up to 4 for severe involvement): 0 = none 1. = slight 2. = moderate 3. = severe 4. = very severe The various body regions are weighted to reflect their respective proportion of BSA.
Time frame: Baseline, Week 104
Change From Baseline in Leeds Enthesitis Index (LEI) for Participants With Enthesitis Related Arthritis (ERA) at Baseline (OLT Period)
The LEI was developed specifically for use in psoriatic arthritis (PsA). It measures enthesitis at 6 sites (lateral epicondyle of humerus, right/left (R/L); medial femoral condyle, (R/L); Achilles tendon insertion, (R/L)). Each site is assigned a score of 0 (absent) or 1 (present); the results from each site are then added to produce a total score (range 0 to 6) with the higher scores indicating more severe enthesitis.
Time frame: Baseline, Week 16
Change From Baseline in Leeds Enthesitis Index (LEI) for Participants With Enthesitis Related Arthritis (ERA) at Baseline (OLE Period)
The LEI was developed specifically for use in psoriatic arthritis (PsA). It measures enthesitis at 6 sites (lateral epicondyle of humerus, right/left (R/L); medial femoral condyle, (R/L); Achilles tendon insertion, (R/L)). Each site is assigned a score of 0 (absent) or 1 (present); the results from each site are then added to produce a total score (range 0 to 6) with the higher scores indicating more severe enthesitis.
Time frame: Baseline, Week 104
Percentage of Participants With Disease Flare (OLT Period)
Disease flare is defined as worsening of ≥30% from baseline in at least 3 of the 6 JIA ACR core set criteria and an improvement of ≥30% in no more than one of the criteria. The JIA ACR, is comprised of 6 core set variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]).
Time frame: Week 2 through Week 16
Percentage of Participants With Disease Flare (OLE Period)
Disease flare is defined as worsening of ≥30% from baseline in at least 3 of the 6 JIA ACR core set criteria and an improvement of ≥30% in no more than one of the criteria. The JIA ACR, is comprised of 6 core set variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]).
Time frame: Baseline through Week 104
Pharmacokinetics (PK): Trough Concentrations (C-trough) of Ixekizumab (Ixekizumab - OLT Period)
C-trough were measured at specified time points to assess the minimum concentration of ixekizumab in the blood before the next dose was administered.
Time frame: Week 4, 12 and 16 : Pre-dose
Pharmacokinetics (PK): Trough Concentrations (C-trough) of Ixekizumab (Ixekizumab - OLE Period)
C-trough were measured at specified time points to assess the minimum concentration of ixekizumab in the blood before the next dose was administered.
Time frame: Week 20, 32, 56, 80 and 104 : Pre-dose
Percentage of Participants With Treatment-emergent Positive Anti-ixekizumab Antibodies (Ixekizumab - OLT Period)
Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.
Time frame: Baseline through Week 16
Percentage of Participants With Treatment-emergent Positive Anti-ixekizumab Antibodies (Ixekizumab - OLE Period)
Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.
Time frame: Baseline through Week 104
The results reported are for the primary outcome up to Week 16 (OLT period); data beyond Week 16 will be reported after study completion, at the time of final results reporting.
| Milestone | Ixekizumab - OLT Period | Adalimumab - OLT Period |
|---|---|---|
| Started | 81 | 20 |
| Received at least one dose of study drug | 81 | 20 |
| Completed | 80 | 19 |
| Not completed | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
JIA ACR, is comprised of 6 variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]). A JIA ACR30 response is defined as at least 30% improvement from baseline in at least 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by more than 30%.
| Percentage of participants | Ixekizumab - OLT Period |
|---|---|
| Percentage of Participants Achieving Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 (Ixekizumab - OLT Period) | 88.9 |
JIA ACR, is comprised of 6 variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]). A JIA ACR30 response is defined as at least 30% improvement from baseline in at least 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by more than 30%.
| Percentage of participants | Adalimumab - OLT Period |
|---|---|
| Percentage of Participants Achieving JIA ACR 30 (Adalimumab - OLT Period) | 95.0 |
JIA ACR, is comprised of 6 core set variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]). A JIA ACR 50/70/90 response is defined as a greater than or equal to (≥) 50/70/90/100% improvement from baseline in at least 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by more than 30%.
| Percentage of participants | Ixekizumab - OLT Period | Adalimumab - OLT Period |
|---|---|---|
| ACR50 response | 79 | 90.0 |
| ACR70 response | 64.2 | 65.0 |
| ACR90 response | 29.6 | 40.0 |
| ACR100 response | 18.5 | 35.0 |
JIA ACR, is comprised of 6 core set variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]). A JIA ACR 30/50/70/90 response is defined as a greater than or equal to (≥) 30/50/70/90/100% improvement from baseline in at least 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by more than 30%.
Results for this outcome have not been posted.
The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling (S), redness (R), and plaque induration/infiltration thickness (T) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Severity is rated for each index (R, S, T) on a 0 to 4 scale (0 for no involvement up to 4 for severe involvement): 0 = none 1. = slight 2. = moderate 3. = severe 4. = very severe The various body regions are weighted to reflect their respective proportion of BSA.
| score on a scale | Ixekizumab - OLT Period | Adalimumab - OLT Period |
|---|---|---|
| Change From Baseline in Psoriasis Area and Severity Index (PASI) for Juvenile Psoriatic Arthritis (JPsA) Participants With at Least 3% Body Surface Area (BSA) at Baseline (OLT Period) | -3.80 ± 3.541 | -0.70 ± NA |
The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling (S), redness (R), and plaque induration/infiltration thickness (T) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Severity is rated for each index (R, S, T) on a 0 to 4 scale (0 for no involvement up to 4 for severe involvement): 0 = none 1. = slight 2. = moderate 3. = severe 4. = very severe The various body regions are weighted to reflect their respective proportion of BSA.
Results for this outcome have not been posted.
The LEI was developed specifically for use in psoriatic arthritis (PsA). It measures enthesitis at 6 sites (lateral epicondyle of humerus, right/left (R/L); medial femoral condyle, (R/L); Achilles tendon insertion, (R/L)). Each site is assigned a score of 0 (absent) or 1 (present); the results from each site are then added to produce a total score (range 0 to 6) with the higher scores indicating more severe enthesitis.
| score on a scale | Ixekizumab - OLT Period | Adalimumab - OLT Period |
|---|---|---|
| Change From Baseline in Leeds Enthesitis Index (LEI) for Participants With Enthesitis Related Arthritis (ERA) at Baseline (OLT Period) | -1.63 ± 1.005 | -1.50 ± 0.577 |
The LEI was developed specifically for use in psoriatic arthritis (PsA). It measures enthesitis at 6 sites (lateral epicondyle of humerus, right/left (R/L); medial femoral condyle, (R/L); Achilles tendon insertion, (R/L)). Each site is assigned a score of 0 (absent) or 1 (present); the results from each site are then added to produce a total score (range 0 to 6) with the higher scores indicating more severe enthesitis.
Results for this outcome have not been posted.
Disease flare is defined as worsening of ≥30% from baseline in at least 3 of the 6 JIA ACR core set criteria and an improvement of ≥30% in no more than one of the criteria. The JIA ACR, is comprised of 6 core set variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]).
| Percentage of participants | Ixekizumab - OLT Period | Adalimumab - OLT Period |
|---|---|---|
| Percentage of Participants With Disease Flare (OLT Period) | 0 | 0 |
Disease flare is defined as worsening of ≥30% from baseline in at least 3 of the 6 JIA ACR core set criteria and an improvement of ≥30% in no more than one of the criteria. The JIA ACR, is comprised of 6 core set variables: number of active joints, number of joints with limited range of motion, Physician's Global Assessment of Disease Activity, Parent's Global Assessment of Well-Being, physical function (measured by the Childhood Health Assessment Questionnaire \[CHAQ\]), and acute-phase reactants (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]).
Results for this outcome have not been posted.
C-trough were measured at specified time points to assess the minimum concentration of ixekizumab in the blood before the next dose was administered.
| micrograms per milliliter (µg/mL) | Ixekizumab - OLT Period (>50 kg Group) | Ixekizumab - OLT Period (25 to 50 kg Group) | Ixekizumab - OLT Period (10 to <25 kg Group) |
|---|---|---|---|
| Week 4 | 4.43 ± 71 | 5.09 ± 38 | 3.28 ± 56 |
| Week 12 | 3.25 ± 68 | 3.39 ± 57 | 2.95 ± 41 |
| Week 16 | 3.47 ± 55 | 3.32 ± 37 | 2.80 ± 46 |
C-trough were measured at specified time points to assess the minimum concentration of ixekizumab in the blood before the next dose was administered.
Results for this outcome have not been posted.
Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.
| Percentage of participants | Ixekizumab - OLT Period |
|---|---|
| Percentage of Participants With Treatment-emergent Positive Anti-ixekizumab Antibodies (Ixekizumab - OLT Period) | 8.8 |
Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.
Results for this outcome have not been posted.
Collected over Baseline up to week 16 (until OLT period). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ixekizumab - OLT Period | 0/81 (0%) | 3/81 (3.7%) | 66/81 (81.5%) |
| Adalimumab - OLT Period | 0/20 (0%) | 3/20 (15%) | 15/20 (75%) |
| Event | Ixekizumab - OLT Period | Adalimumab - OLT Period |
|---|---|---|
| BicytopeniaBlood and lymphatic system disorders | 0/81 | 1/20 |
| Middle ear effusionEar and labyrinth disorders | 0/81 | 1/20 |
| HypertransaminasaemiaHepatobiliary disorders | 0/81 | 1/20 |
| Anaphylactic reactionImmune system disorders | 0/81 | 1/20 |
| CellulitisInfections and infestations | 0/81 | 1/20 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/81 | 1/20 |
| Acute sinusitisInfections and infestations | 1/81 | 0/20 |
| TonsillitisInfections and infestations | 1/81 | 0/20 |
| Acetabulum fractureInjury, poisoning and procedural complications | 1/81 | 0/20 |
| Event | Ixekizumab - OLT Period | Adalimumab - OLT Period |
|---|---|---|
| NasopharyngitisInfections and infestations | 11/81 | 4/20 |
| Injection site reactionGeneral disorders | 13/81 | 1/20 |
| HeadacheNervous system disorders | 13/81 | 2/20 |
| NauseaGastrointestinal disorders | 2/81 | 2/20 |
| Blood cholesterol increasedInvestigations | 0/81 | 2/20 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 8/81 | 2/20 |
| Injection site painGeneral disorders | 8/81 | 0/20 |
| VomitingGastrointestinal disorders | 7/81 | 0/20 |
| Covid-19Infections and infestations | 7/81 | 0/20 |
| Upper respiratory tract infectionInfections and infestations | 7/81 | 0/20 |
As pre-specified in the statistical analysis plan, all randomized participants were reported, per treatment regimen, as exposure was the same across the different treatment groups.
| Age, Continuous(years) | Ixekizumab - OLT Period | Adalimumab - OLT Period | Total |
|---|---|---|---|
| Mean | 13.10 ± 3.07 | 13.30 ± 3.16 | 13.10 ± 3.08 |
| Sex: Female, Male(Participants) | Ixekizumab - OLT Period | Adalimumab - OLT Period | Total |
|---|---|---|---|
| Female | 36 | 8 | 44 |
| Male | 45 | 12 | 57 |
| Ethnicity (NIH/OMB)(Participants) | Ixekizumab - OLT Period | Adalimumab - OLT Period | Total |
|---|---|---|---|
| Hispanic or Latino | 26 | 4 | 30 |
| Not Hispanic or Latino | 26 | 5 | 31 |
| Unknown or Not Reported | 29 | 11 | 40 |
| Race (NIH/OMB)(Participants) | Ixekizumab - OLT Period | Adalimumab - OLT Period | Total |
|---|---|---|---|
| American Indian or Alaska Native | 11 | 4 | 15 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 69 | 15 | 84 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Ixekizumab - OLT Period | Adalimumab - OLT Period | Total |
|---|---|---|---|
| Argentina | 8 | 1 | 9 |
| Belgium | 2 | 1 | 3 |
| Czechia | 3 | 0 | 3 |
| France | 3 | 0 | 3 |
| Germany | 21 | 10 | 31 |
| Italy | 7 | 0 | 7 |
| Mexico | 17 | 4 | 21 |
| Netherlands | 1 | 0 | 1 |
| Spain | 5 | 0 | 5 |
| Switzerland | 1 | 1 | 2 |
| United Kingdom | 13 | 3 | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Apr 2021 to primary completion in Feb 2024, 34 months.
Results were first posted in Jun 2025, 1 year 3 months after primary completion.
Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 34 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab